1. Home
  2. SMTI vs LUNG Comparison

SMTI vs LUNG Comparison

Compare SMTI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sanara MedTech Inc.

SMTI

Sanara MedTech Inc.

HOLD

Current Price

$22.85

Market Cap

182.6M

Sector

Health Care

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.54

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMTI
LUNG
Founded
1982
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.6M
57.9M
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
SMTI
LUNG
Price
$22.85
$1.54
Analyst Decision
Strong Buy
Buy
Analyst Count
2
7
Target Price
$34.00
$5.38
AVG Volume (30 Days)
37.9K
520.2K
Earning Date
05-12-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
0.05
N/A
Revenue
$15,586,976.00
$90,497,000.00
Revenue This Year
$17.31
$2.48
Revenue Next Year
$12.48
$18.46
P/E Ratio
$476.50
N/A
Revenue Growth
32.47
8.01
52 Week Low
$16.05
$1.13
52 Week High
$35.70
$3.88

Technical Indicators

Market Signals
Indicator
SMTI
LUNG
Relative Strength Index (RSI) 65.71 66.44
Support Level $22.60 $1.51
Resistance Level $25.14 $1.64
Average True Range (ATR) 1.48 0.09
MACD 0.38 0.04
Stochastic Oscillator 79.73 82.34

Price Performance

Historical Comparison
SMTI
LUNG

About SMTI Sanara MedTech Inc.

Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: